Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American

Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple
  PCI-32765 Presentations at the 54th American Society of Hematology Annual
                                   Meeting

PR Newswire

SUNNYVALE, Calif., Nov. 5, 2012

SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the
"Company") (Nasdaq: PCYC) today reported financial results and recent
developments for its fiscal 2013 first quarter ended September 30, 2012.

Financial Results for First Quarter Ended September 30, 2012

The GAAP (Generally Accepted Accounting Principles) net income for the fiscal
quarter ended September 30, 2012 was $75.6 million, or $1.09 and $1.02 per
basic and diluted earnings per share, respectively. This compares with a GAAP
net loss of $14.5 million, or $0.21 loss per basic and diluted share for the
fiscal quarter ended September 30, 2011.

The non-GAAP net income reported for the fiscal quarter ended September 30,
2012 was $78.8 million, or $1.14 and $1.07 income per basic and diluted
earnings per share, respectively. This compares with a non-GAAP net loss of
$12.4 million, or $0.18 basic and diluted loss per share, for the fiscal
quarter ended September 30, 2011. See "Use of Non-GAAP Financial Measures"
below for a description of our Non-GAAP measures. Reconciliation between
certain GAAP and non-GAAP measures is provided at the end of this press
release.

Revenue for the fiscal quarter ended September 30, 2012 was $102.7 million,
compared to $37,000 for the fiscal quarter ended September 30, 2011, an
increase of approximately $102.7 million. Revenue for the fiscal quarter ended
September 30, 2012 consisted primarily of $100 million of license and
milestone revenue due to the Company's achievement of two clinical milestones
in connection with the Company's collaboration and license agreement (the
"Agreement") with Janssen Biotech, Inc. ("Janssen").

At September 30, 2012, the Company had cash, cash equivalents and marketable
securities of $286.1 million, which compares with $203.6 million at June 30,
2012. Total operating expenses excluding share based compensation during the
quarter ending September 30, 2012 were $20.8 million compared to $17.8 million
during the quarter ending June 30, 2012. The Company also had $8.6 million due
from Janssen at September 30, 2012 in connection with the Agreement.
Additionally, as announced on October 15, 2012, the Company triggered a $50
million milestone payment obligation from Janssen under the Agreement as a
result of the enrollment of a fifth patient in a study of ibrutinib
(PCI-32765) in combination with bendamustine and rituximab in patients with
relapsed or refractory chronic lymphocytic leukemia. The Company received the
$50 million milestone payment from Janssen in October 2012.

To date, the Company has received three milestone payments from Janssen of $50
million each under the Agreement. The Company may receive up to an additional
$675 million in development and regulatory milestone payments, however
clinical development entails risks and the Company has no assurance as to
whether or when the milestone targets might be achieved.

On October4, 2012, the Company entered into a strategic license agreement
with Novo Nordisk A/S. Novo Nordisk acquired the exclusive worldwide rights
for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a
restricted disease indication outside of oncology. Novo Nordisk will utilize
PCI-27483 as an excipient in a product within Novo Nordisk's biopharmaceutical
unit. In connection with entering into this agreement, the Company is entitled
to an upfront payment of $5 million which was received in October 2012. In
addition, the Company may receive up to $55 million based on the achievement
of certain development, regulatory and sales milestones. Upon
commercialization, the Company will also receive low single digit tiered
royalties on Novo Nordisk net sales of biopharmaceutical formulations
utilizing the addition of PCI-27483.

Recent Developments & Highlights

Nine Oral Presentations and Seven Poster Presentations for our BTK Inhibitor
Ibrutinib (PCI-32765) and one Oral Presentation and one Poster Presentation
for our HDAC Inhibitor Abexinostat (PCI-24781) have been accepted at the
American Society of Hematology (ASH) Annual Meeting in Atlanta, GA (December
8-11, 2012). These abstracts will be published today on the ASH website at
www.hematology.org at approximately 10:00 a.m. ET. They are showing overall
clinical and pre-clinical progress in many programs to date. Clinical
presentations scheduled during the ASH annual meeting in December will provide
further updates to these abstracts regarding the efficacy and safety of
ibrutinib (PCI-32765), particularly in chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma.

Early Phase I data in follicular lymphoma and Phase II data in diffuse large
b-cell lymphoma (DLBCL) will also be provided at ASH. As the clinical path for
DLBCL will continue to evolve further, we expect to provide additional color
in the second half of 2013. We are also reporting on a first, small cohort of
multiple myeloma (MM) patients. We learned that single agent ibrutinib at 420
mg is tolerable to administer but did not produce defined objective responses
(PR, CRs) at this dose. There were, however, several patients that achieved
stable disease and minor response. We have expanded the program to understand
the drug's response at higher doses (560 mg and 840 mg) and in combination
with dexamethasone at the 560 mg and potentially 840 mg dose. As we obtain
further data from these cohorts over the next 12 months, we will assess the
clinical outcome of ibrutinib in this patient population. At this time, we do
not expect to further evaluate single agent ibrutinib at the 420 mg dose in
MM. 

Additionally, the investigation of ibrutinib (PCI-32765) for the treatment of
patients with CLL/SLL who have relapsed or have refractory disease and have
previously received at least one prior therapy was designated as a Fast Track
Development Program by the Division of Hematology Products, Office of
Hematology and Oncology Products, a department of the FDA.

An update to the ASH published abstracts and progress on our clinical trials
will be provided in a conference call following the ASH presentations on
December 12, 2012. Until that time, we will adhere to the ASH embargo and not
discuss the ASH presentations further in public.

Clinical ASH Presentations for BTK Inhibitor Ibrutinib (PCI-32765)

  oMantle Cell Lymphoma Oral Presentation
    Title: Interim Results of an International, Multicenter, Phase 2 Study of
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in
    Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and
    Tolerability with Longer Follow-up
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding
    Pre-Clinical Models: Optimizing Current Treatment Strategies
    Date/Time: Tuesday, December 11, 2012 Presentation Time: 8:15 AM
    Location: Georgia World Congress Center, B405-B407
    Presenter: Michael (Luhua) Wang
  oChronic Lymphocytic Leukemia Oral Presentation
    Title: The Btk inhibitor Ibrutinib in combination with rituximab is well
    tolerated and displays profound activity in high-risk Chronic Lymphocytic
    Leukemia (CLL) patients
    Session: 642. CLL - Therapy, excluding Transplantation: New Targeted
    Therapies
    Date/Time: Sunday, December 9, 2012 Presentation Time: 4:30 PM
    Location: Georgia World Congress Center, Thomas Murphy Ballroom 4
    Presenter: Jan Burger
  oChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib Promotes
    High Response Rate, Durable Remissions, and Is Tolerable in Treatment
    Naïve (TN) and Relapsed or Refractory (RR) CLL or SLL Patients Including
    Patients with High-Risk (HR) Disease: New and Updated Results of 116
    Patients in a Phase Ib/II Study
    Session: 642. CLL - Therapy, excluding Transplantation: New Targeted
    Therapies
    Date/Time: Sunday, December 9, 2012 Presentation Time: 5:00 PM
    Location: Georgia World Congress Center, Thomas Murphy Ballroom 4
    Presenter: John Byrd
  oDiffuse Large B-Cell Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, has
    Preferential Activity in the ABC Subtype of Relapsed/Refractory de Novo
    Diffuse Large B-cell Lymphoma (DLBCL): Interim Results of a Multicenter,
    Open-label, Phase 2 Study
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models:
    Aggressive B-Cell Lymphoma
    Date/Time: Monday, December 10, 2012 Presentation Time: 4:45 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium
    Presenter: Wyndham Wilson
  oFollicular Lymphoma Oral Presentation
    Title: The Bruton's Tyrosine Inhibitor Ibrutinib (PCI-32765) is Active and
    Tolerated in Relapsed Follicular Lymphoma
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models:
    Mantle Cell Lymphoma and Follicular Lymphoma
    Date/Time: Sunday, December 9, 2012 Presentation Time: 5:45 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium
    Presenter: Nathan Fowler
  oMultiple Myeloma Poster Presentation
    Title: Early Changes in Cytokines, Chemokines and Indices of Bone
    Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk)
    Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or
    Relapsed/Refractory MM
    Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III
    Date/Time: Monday, December 10, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Ravi Vij
  oNon-Hodgkin's Lymphoma Poster Presentation
    Title: A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor,
    Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine
    in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding
    Pre-Clinical Models: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Kristie Blum
  oChronic Lymphocytic Leukemia Poster Presentation
    Title: Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in
    CLL Despite Transient Increase in ALC Indicates a Significant Degree of
    Treatment Induced Cell Death
    Session: 642. CLL - Therapy, excluding Transplantation: Poster II
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mohammed Farooqui
  oChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Poster
    Presentation
    Title: Ibrutinib rapidly improves platelet counts in chronic lymphocytic
    leukemia / small lymphocytic lymphoma (CLL/SLL) patients and has minimal
    effects on platelet aggregation
    Session: 642. CLL - Therapy, excluding Transplantation: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mohammed Farooqui

Clinical ASH Presentations for HDAC Inhibitor Abexinostat (PCI-24781)

  oFollicular Lymphoma & Mantle Cell Lymphoma Oral Presentation
    Title: A Phase II Multicenter Study of the Histone Deacetylase Inhibitor
    (HDACi) Abexinostat (PCI-24781) in Relapsed/ Refractory Follicular
    Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
    Session: 624. Lymphoma - Therapy with Biologic Agents, excluding
    Pre-Clinical Models: Novel Agents and Targeted Therapies
    Date/Time: Sunday, December 9, 2012 Presentation Time: 12:00 PM
    Location: Georgia World Congress Center, Sidney Marcus Auditorium
    Presenter: Andrew Evens
  oHodgkin's Lymphoma, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
    Poster Presentation
    Title: Abexinostat (S 78454), an oral Histone Deacetylase (HDAC) Inhibitor
    in patients with refractory or relapsed Hodgkin's Lymphoma, non-Hodgkin
    Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I
    dose-escalation study in 35 patients
    Session: 623. Lymphoma - Chemotherapy, excluding Pre-Clinical Models:
    Poster III
    Date/Time: Monday, December 10, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: F. Morschhauser

Non-Clinical ASH Presentations

  oChronic Lymphocytic Leukemia Oral Presentation
    Title: In vivo inhibition of BCR activation in high-risk CLL patients on
    therapy with Bruton's tyrosine kinase inhibitor Ibrutinib: correlative
    studies from an ongoing Phase 2 clinical trial
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR
    and clone dynamics in mice and men
    Date/Time: Sunday, December 9, 2012 Presentation Time: 5:45 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Julia Hoellenriegel
  oChronic Lymphocytic Leukemia Oral Presentation
    Title: In Vivo Effects of Ibrutinib on BCR Signaling, Tumor Cell
    Activation and Proliferation in Blood and Tissue-Resident Cells of Chronic
    Lymphocytic Leukemia Patients
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR
    and clone dynamics in mice and men
    Date/Time: Session Date: Sunday, December 9, 2012 Presentation Time:
    5:30 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Sarah Herman
  oChronic Lymphocytic Leukemia Oral Presentation
    Title: Global inhibition of Bruton's Tyrosine Kinase (Btk) Delays the
    Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the
    TCL1 Mouse Model of Disease
    Session: 641. CLL - Biology and Pathophysiology, excluding Therapy: BCR
    and clone dynamics in mice and men
    Date/Time: Sunday, December 9, 2012 Presentation Time: 5:00 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Jennifer Woyach
  oChronic Lymphocytic Leukemia Oral Presentation
    Title: Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2
    Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1
    Selective Pressure in CD4 T-Cells
    Session: 604. Molecular Pharmacology, Drug Resistance: Therapeutic
    Exploitation of Oncogenic and Metabolic Pathways in Lymphoma and Leukemia
    Date/Time: Monday, December 10, 2012 Presentation Time: 6:15 PM
    Location: Georgia World Congress Center, B211-B212
    Presenter: Jason Dubovsky
  oHairy Cell Leukemia Poster Presentation
    Title: Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765)
    blocks hairy cell leukemia (HCL) survival, proliferation, and BCR
    signaling: a new therapeutic approach for HCL
    Session: 642. CLL - Therapy, excluding Transplantation: Poster I
    Date/Time: Saturday, December 8, 2012, 5:30 PM - 7:30 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Mariela Sivina
  oB-cell Acute Lymphoblastic Leukemia Poster Presentation
    Title: Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib
    (PCI-32765) in B-cell Acute Lymphoblastic Leukemia (B-ALL)
    Session: 612. Acute Lymphoblastic Leukemia - Pathophysiology & Clinical
    Studies: Poster II
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Ekaterina Kim
  oChronic Lymphocytic Leukemia Poster Presentation
    Title: BTK Inhibition Targets In Vivo CLL Proliferation Through Its
    Effects On B-Cell Receptor Signaling Activity
    Session: 642. CLL - Therapy, excluding Transplantation: Poster II
    Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM
    Location: Georgia World Congress Center, Hall B1-B2
    Presenter: Y Lynn Wang

Conference Call and further Corporate Updates

The Company will host a conference call and webcast on Wednesday, December 12,
2012, to provide an overview of the data presented at the ASH Annual Meeting
and give a corporate update discussing future clinical development plans.

During the next open trading window which commences on November 7, 2012, we
expect that certain employees may exercise options they hold, and sell the
shares immediately following the exercise. Our CEO and Chairman, Robert W.
Duggan, has advised us that he does not anticipate selling any of his shares
at the present time.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including operating
expenses and other expenses adjusted to exclude certain non-cash expenses.
These measures are not in accordance with, or an alternative to generally
accepted accounting principles, or GAAP, and may be different from non-GAAP
financial measures used by other companies. The items included in GAAP
presentations but excluded for purposes of determining non-GAAP financial
measures for the periods presented in this press release are employee related
non-cash expenses. The Company believes the presentation of non-GAAP financial
measures provides useful information to management and investors regarding
various financial and business trends relating to our financial condition and
results of operations. When GAAP financial measures are viewed in conjunction
with non-GAAP financial measures, investors are provided with a more
meaningful understanding of our ongoing operating performance. In addition,
these non-GAAP financial measures are among those indicators the Company uses
as a basis for evaluating operational performance, allocating resources and
planning and forecasting future periods. Non-GAAP financial measures are not
intended to be considered in isolation or as a substitute for GAAP financial
measures. To the extent this release contains historical non-GAAP financial
measures, the Company has also provided corresponding GAAP financial measures
for comparative purposes. Reconciliation between certain GAAP and non-GAAP
measures is provided below.

About Pharmacyclics

Pharmacyclics^® is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative small-molecule drugs for the
treatment of cancer and immune mediated diseases. Our mission and goal is to
build a viable biopharmaceutical company that designs, develops and
commercializes novel therapies intended to improve quality of life, increase
duration of life and resolve serious unmet medial healthcare needs; and to
identify promising product candidates based on scientific development
expertise, develop our products in a rapid, cost-efficient manner and pursue
commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development
and several preclinical molecules in lead optimization. The Company is
committed to high standards of ethics, scientific rigor, and operational
efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ
under the symbol PCYC. To learn more about how Pharmacyclics advances science
to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in
reliance upon the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, including statements, among others, relating to our future capital
requirements and the sufficiency of our current assets to meet these
requirements, our future results of operations, our expectations for and
timing of ongoing or future clinical trials and regulatory approvals for any
of our product candidates, and our plans, objectives, expectations and
intentions. Because these statements apply to future events, they are subject
to risks and uncertainties. When used in this announcement, the words
"anticipate", "believe", "estimate", "expect", "expectation", "should",
"would", "project", "plan", "predict", "intend" and similar expressions are
intended to identify such forward-looking statements. These forward-looking
statements are based on information currently available to us and are subject
to a number of risks, uncertainties and other factors that could cause our
actual results, performance or achievements to differ materially from those
projected in, or implied by, these forward-looking statements. Factors that
may cause such a difference include, without limitation, our need for
substantial additional financing and the availability and terms of any such
financing, the safety and/or efficacy results of clinical trials of our
product candidates, our failure to obtain regulatory approvals or comply with
ongoing governmental regulation, our ability to commercialize, manufacture and
achieve market acceptance of any of our product candidates, for which we rely
heavily on collaboration with third parties, and our ability to protect and
enforce our intellectual property rights and to operate without infringing
upon the proprietary rights of third parties. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, performance or achievements and no assurance
can be given that the actual results will be consistent with these
forward-looking statements. For more information about the risks and
uncertainties that may affect our results, please see the Risk Factors section
of our filings with the Securities and Exchange Commission, including our
annual report on Form 10-K and quarterly reports on Form 10-Q. We do not
intend to update any of the forward-looking statements after the date of this
announcement to conform these statements to actual results, to changes in
management's expectations or otherwise, except as may be required by law.



Pharmacyclics, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands)
                                                  September 30,   June 30,

                                                   2012          2012
ASSETS
 Cash and cash equivalents                    $ 276,187       $ 197,896
 Marketable securities                          9,916           5,711
 Other current assets                           11,406          9,788
 Total current assets                        297,509         213,395
 Property and equipment, net                    4,975           3,842
 Other assets                                   2,074           1,883
 Total assets                              $ 304,558       $ 219,120
LIABILITIES AND STOCKHOLDERS' EQUITY
 Deferred revenue – current portion           $ 7,978         $ 8,054
 Other current liabilities                      17,844          10,932
 Total current liabilities                   25,822          18,986
 Deferred revenue – non-current portion         64,804          67,324
 Deferred rent                                  765             687
 Total liabilities                            91,391          86,997
 Stockholders' equity                           213,167         132,123
 Total liabilities and stockholders' equity $ 304,558       $ 219,120



Pharmacyclics, Inc.

Condensed Consolidated Statements of Operations
(unaudited; in thousands, except per share data)
                                                            Three Months Ended

                                                            September 30,
                                                            2012      2011
Revenue:
 License and milestone revenue                          $ 100,000 $ -
 Collaboration services revenue                           2,695     37
 Total revenue                                         102,695   37
Operating expenses*:
 Research and development                                 19,072    11,248
 General and administrative                               4,868     3,350
 Total operating expenses                              23,940    14,598
Income (loss) from operations                               78,755    (14,561)
Interest and other income, net                              52        23
Income (loss) before income taxes                           78,807    (14,538)
Income tax (provision) benefit                              (3,201)   -
Net income (loss)                                         $ 75,606  $ (14,538)
Net income (loss) per share:
Basic                                                     $ 1.09    $ (0.21)
Diluted                                                   $ 1.02    $ (0.21)
Weighted average shares used to compute net income (loss)
per share:
Basic                                                       69,512    68,323
Diluted                                                     74,456    68,323
* Includes share-based compensation as follows:
Research and development                                  $ 2,590   $ 1,538
General and administrative                                  576       626
Total                                                     $ 3,166   $ 2,164





Reconciliation of Selected GAAP Measures to Non-GAAP Measures ^(1)

(unaudited; in thousands, except per share data)
                                                        Three Months Ended

                                                        September 30,
                                                        2012      2011
GAAP net income (loss)                                $ 75,606  $ (14,538)
Adjustments:
Research & development share-based compensation^(2)     2,590     1,538
General & administrative share-based compensation^(2)   576       626
                                                        3,166     2,164
Non-GAAP net income (loss)                            $ 78,772  $ (12,374)
GAAP net income (loss) per share – basic              $ 1.09    $ (0.21)
 Share-based compensation expense                   0.04      0.03
Non-GAAP net income (loss) per share – basic          $ 1.13    $ (0.18)
GAAP net income (loss) per share – diluted            $ 1.02    $ (0.21)
 Share-based compensation expense                   0.04      0.03
Non-GAAP net income (loss) per share – diluted        $ 1.06    $ (0.18)

    This presentation includes non-GAAP measures. Our non-GAAP measures are
(1) not meant to be considered in isolation or as a substitute for comparable
    GAAP measures and should be read only in conjunction with our financial
    statements prepared in accordance with GAAP.
(2) All share-based compensation was excluded for the non-GAAP analysis.

SOURCE Pharmacyclics, Inc.

Website: http://www.pharmacyclics.com
Contact: Joshua T. Brumm, Executive Vice President, Finance, +1-408-215-3311;
Ramses Erdtmann, Vice President of Investor Relations, +1-408-215-3325
 
Press spacebar to pause and continue. Press esc to stop.